Esperion Therapeutics (NASDAQ:ESPR) Lifted to “Buy” at StockNews.com

StockNews.com upgraded shares of Esperion Therapeutics (NASDAQ:ESPR) from a hold rating to a buy rating in a research note released on Thursday.

A number of other research firms have also recently commented on ESPR. HC Wainwright reissued a buy rating and set a $16.00 target price on shares of Esperion Therapeutics in a research note on Monday, August 12th. Bank of America cut Esperion Therapeutics from a neutral rating to an underperform rating and reduced their target price for the company from $2.90 to $2.50 in a report on Thursday, June 20th. Finally, Needham & Company LLC dropped their price target on Esperion Therapeutics from $8.00 to $6.00 and set a buy rating for the company in a research report on Tuesday, August 13th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of Hold and an average price target of $8.17.

Esperion Therapeutics Trading Down 4.0 %

Shares of ESPR stock opened at $1.68 on Thursday. The company has a market capitalization of $318.29 million, a P/E ratio of -1.70 and a beta of 1.00. Esperion Therapeutics has a 12-month low of $0.70 and a 12-month high of $3.40. The business’s 50 day moving average is $1.99 and its two-hundred day moving average is $2.22.

Esperion Therapeutics (NASDAQ:ESPR) last announced its earnings results on Monday, August 12th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.10. The business had revenue of $73.83 million for the quarter, compared to analysts’ expectations of $51.90 million. On average, research analysts predict that Esperion Therapeutics will post -0.04 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in ESPR. Capital Advisors Wealth Management LLC lifted its position in Esperion Therapeutics by 22.9% during the second quarter. Capital Advisors Wealth Management LLC now owns 26,800 shares of the biopharmaceutical company’s stock worth $59,000 after buying an additional 5,000 shares in the last quarter. Summit Financial LLC raised its holdings in shares of Esperion Therapeutics by 26.4% during the 2nd quarter. Summit Financial LLC now owns 32,687 shares of the biopharmaceutical company’s stock worth $73,000 after acquiring an additional 6,823 shares during the period. National Bank of Canada FI boosted its position in shares of Esperion Therapeutics by 115.9% during the 2nd quarter. National Bank of Canada FI now owns 19,050 shares of the biopharmaceutical company’s stock valued at $44,000 after acquiring an additional 10,225 shares during the last quarter. GSA Capital Partners LLP boosted its position in shares of Esperion Therapeutics by 1.0% during the 4th quarter. GSA Capital Partners LLP now owns 1,128,149 shares of the biopharmaceutical company’s stock valued at $3,373,000 after acquiring an additional 11,494 shares during the last quarter. Finally, SG Americas Securities LLC increased its position in Esperion Therapeutics by 45.3% during the second quarter. SG Americas Securities LLC now owns 37,414 shares of the biopharmaceutical company’s stock worth $83,000 after purchasing an additional 11,658 shares during the last quarter. 47.39% of the stock is currently owned by institutional investors and hedge funds.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.